FY2025 · ended Dec 31, 2025 · Revenue $7.83M, -58.2% YoY · Filed Feb 26, 2026
Aclaris Therapeutics, Inc. (ACRS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.8 million and a net loss of $64.9 million. Free cash flow was -$47.2 million. As of Jun 30, 2026 it held $170.6 million in cash and investments and $1.9 million in total debt.
Revenue (TTM)
$8.22M
-51.0% vs year-ago TTM
Net income (TTM)
$-75.74M
+43.8% vs year-ago TTM
Operating cash flow (TTM)
$-62.06M
-521.3% vs year-ago TTM
Free cash flow (TTM)
$-62.18M
-518.6% vs year-ago TTM
EPS (TTM)
$-0.59
+55.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
120.60M
+11.7% vs prior year
Net cash
$168.77M
as of Jun 30, 2026
Operating margin
-1050.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557746
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M |
| Diluted EPS | -$0.53 | -$1.71 | -$1.27 | -$1.33 | -$1.60 |
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M |
| Stockholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
| Cash and investments | $151.4M | $203.9M | $181.9M | $229.8M | $225.7M |
| Total debt | $2.1M | $2.6M | $3.5M | $2.3M | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
All 870 Aclaris Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.